DE | Accessible presentation
Translations are powered by AI

These Munich startups are ripe for investment

Which startups have the best prospects of successfully completing a financing round soon? We take a look into the crystal ball and introduce you to five companies that are ripe for investment.

June 18, 2024 4 min reading time

Catalym
Catalym develops new active ingredients for immunotherapies that aim to target the body's own immune system against cancer. A major challenge is to combine a highly effective immune response against cancer cells with minimal side effects. The Munich-based startup is focusing on the drug candidate VisugromabThis is intended to neutralize a specific protein that tumors use to protect themselves from the body's own immune system. This should make the cancer cells accessible to the immune system again, which should strengthen the immune system. With this idea, which goes back to research at the University of Würzburg, the startup has already convinced numerous investors. Most recently, Catalym closed its Series C of €50 million in November 2022. From the perspective of the Dealroom Signal, in addition to this timing (100 points), the founding team (94 points) and the growth rate (86 points) are convincing. The overall score thus comes to 89 points.
read more ↓